The Bulletin
The Times


.

T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors

  • Written by PR Newswire

MT027 has previously been granted FDA Orphan Drug Designation and has entered Phase II clinical development in recurrent glioblastoma

BEIJING, Aug. 31, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") today announced that its investigational allogeneic CAR-T cell therapy MT027 has been granted Fast Track Designation (FTD) by...

hacklink esim balkanSahabetuk casinos not on gamstopGamStopgrandpashabet girisjojobetviagra 100 mg fiyat